Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can...

With atopic dermatitis rivals breathing down Dupixent’s neck, Sanofi and Regeneron on Friday secured a first win in new territory in what Sanofi’s head...

Yesterday, the team at All Blue Capital — bent on the takeover of a badly battered Zymeworks — brought in celebrated oncologist, Pulitzer prize-winning...

The FDA is tapping the brakes on a Flagship-backed biotech’s R&D efforts to develop a new treatment for blood cancers after a patient died...

Two months after Atara Biotherapeutics hit the hold button on its lead CAR-T 2.0 therapy following a patient death, putting the company under the...

Two months after Atara Biotherapeutics hit the hold button on its lead CAR-T 2.0 therapy following a patient death, putting the company under the...

Two months after Atara Biotherapeutics hit the hold button on its lead CAR-T 2.0 therapy following a patient death, putting the company under the...

New FDA commissioner Rob Califf told staff in a memo yesterday evening that longtime drug center director Janet Woodcock, who’s now serving as Califf’s...

Martin Shkreli, the infamous biotech CEO who made headlines for his jeering assault on a legion of critics in and out of Congress, is...

  • 1527038951210483714 Profile photo of Madelyn

    Some stories you follow because it's fun or interesting or necessary. Then there's Martin Shkreli, who's like a bad tattoo you got one drunk night in New Orleans. It just won't go away. https://t.co/gAAHvEuejj - view on twitter

Flagship has crafted a new startup out of pieces from a pair of fledglings in the VC’s nest. And a prominent Roche veteran who...